Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects
Status:
Completed
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects
will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will
be based on the subject's body weight.